Denali Therapeutics Inc
Research Denali Therapeutics Inc (DNLI) on Bullrun: market cap USD 3.98B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDNLI
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.98B
- Financial periodQ2 2026
- RevenueUSD 3.60M
- Net income-USD 127.55M
- Free cash flow-USD 126.61M
- Gross margin97.4%
Valuation Snapshot
latest market cap is USD 3.98B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 512.54M | -USD 422.10M | n/a | -2.97 | USD 205.33M | USD 36.76M | USD 1.01B |
| FY2024 | USD 0 | -USD 422.77M | -USD 363.61M | n/a | -2.57 | USD 174.96M | USD 48.71M | USD 1.23B |
| FY2023 | USD 330.53M | -USD 145.22M | -USD 370.93M | n/a | -1.06 | USD 127.11M | USD 52.24M | USD 1.03B |
| FY2022 | USD 105.07M | -USD 325.99M | -USD 262.55M | n/a | -2.6 | USD 218.04M | USD 61.40M | USD 1.04B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 3.98B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.58B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.94B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.97B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 3.78B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 5.45B | n/a | n/a | n/a |
About Denali Therapeutics Inc
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A);
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Denali Therapeutics Inc's market cap?
Denali Therapeutics Inc's market capitalization is USD 3.98B.
What does Denali Therapeutics Inc do?
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).